Lv1
20 积分 2024-08-07 加入
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
2个月前
已完结
Building blocks for bispecific and trispecific antibodies
2个月前
已完结
BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy
2个月前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
4个月前
已完结
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
8个月前
已完结
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
8个月前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
10个月前
已完结
Cutaneous melanoma
1年前
已完结
皖公网安备34019202002308
